| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.03 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.068 | 0.03 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.04 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.076 | 0.04 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.04 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.11 | 0.04 |